Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

被引：0
|
作者：
Hernando-Cubero, J. [1 ]
Manzano, J. L. [2 ]
Benavent, M. [3 ]
Lopez, C. [4 ]
Teule, R. [5 ]
Garcia-Carbonero, R. [6 ]
Carmona-Bayonas, A. [7 ]
Crespo, G. [8 ]
Cubillo, A. [9 ]
Jimenez-Fonseca, P. [10 ]
LaCasta, A. [11 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Inst Catala Oncol Badalona, Barcelona, Spain
[3] Hosp Virgen del Rocio, Seville, Spain
[4] Hosp Univ Marques de Valdecilla, Santander, Spain
[5] Inst Catala Oncol Hosp, Barcelona, Spain
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] HJM Morales Meseguer, Murcia, Spain
[8] Hosp Univ Burgos, Burgos, Spain
[9] Hosp Univ Madrid Sanchinarro, Madrid, Spain
[10] Hosp Univ Cent Asturias, Oviedo, Spain
[11] Hosp Univ Donostia, San Sebastian, Spain
来源：
NEUROENDOCRINOLOGY | 2018年 / 106卷
关键词：
durvalumab; tremelimumab; neuroendocrine; immunotherapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
J10
引用
收藏
页码：228 / 228
页数：1
相关论文
共 50 条
  • [11] Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
    Castillon, J. Capdevila
    Plana, M.
    Castelo, B.
    Iglesias, L.
    Hernando, J.
    Tur, R. Yaya
    Baste, N.
    Carmona-Bayonas, A.
    Ruiz, S.
    Trigo, J.
    Lorenzo-Lorenzo, I.
    Grande, E.
    Lorente, D.
    Ugidos, L.
    Marquina, G.
    Garcia-Alvarez, A.
    Taberna, M.
    Villamayor, J.
    Molina-Cerrillo, J.
    Alonso-Gordoa, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1294 - S1295
  • [12] Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) - DUTHY (GETNE-T1812) trial
    Garcia-Alvarez, A.
    Molina-Cerrillo, J.
    Castelo, B.
    Plana, M.
    Iglesias, L.
    Carmona-Bayonas, A.
    Yaya, Tur R.
    Ruiz, S.
    Baste, N.
    Lorenzo-Lorenzo, I
    Alonso-Gordoa, T.
    Capdevila, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 236 - 236
  • [13] Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)
    Molina-Cerrillo, J.
    Grande, E.
    Benavent, M.
    Garcia-Carbonero, R.
    Teule, A.
    Custodio, A.
    Jimenez-Fonseca, P.
    Hierro, C.
    Lopez, C.
    Sevilla, I
    Llanos, M.
    Capdevila, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 245 - 245
  • [14] A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial
    Clemente, O.
    Starita, N.
    Bracigliano, A.
    Cives, M.
    Tatangelo, F.
    Barretta, M. L.
    Badalamenti, G.
    Lastoria, S.
    Picozzi, F.
    Di Mauro, A.
    von Arx, C.
    Cannella, L.
    Tafuto, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S708 - S708
  • [15] Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
    Riesco Martinez, M. C.
    Capdevila Castillon, J.
    Alonso, V.
    Jimenez-Fonseca, P.
    Teule, A.
    Grande, E.
    Sevilla, I.
    Benavent, M.
    Alonso-Gordoa, T.
    Custodio, A.
    Anton Pascual, B.
    Hernando, J.
    Polo, E.
    Castillo Trujillo, O. A.
    Garcia-Carbonero, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S769 - S769
  • [16] Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
    Riesco-Martinez, M. C.
    Capdevila, J.
    Alonso, V.
    Jimenez-Fonseca, P.
    Teule, A.
    Grande, E.
    Sevilla, I.
    Benavent Vinuales, M.
    Alonso-Gordoa, T.
    Custodio, A.
    Hernando, J.
    Polo, E.
    Castillo Trujillo, O. A.
    Garcia-Carbonero, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S908 - S909
  • [17] Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)
    Riesco-Martinez, Maria Carmen
    Capdevila, Jaume
    Alonso, Vicente
    Jimenez-Fonseca, Paula
    Teule, Alex
    Grande, Enrique
    Sevilla, Isabel
    Benavent, Marta
    Alonso-Gordoa, Teresa
    Custodio, Ana
    Anton-Pascual, Beatriz
    Hernando, Jorge
    Polo, Eduardo
    Castillo-Trujillo, Oscar Alfredo
    Lamas-Paz, Arantza
    Teijo, Ana
    Rodriguez-Gil, Yolanda
    Soldevilla, Beatriz
    Garcia-Carbonero, Rocio
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [18] NICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913
    Riesco Martinez, M. C.
    Capdevila, J.
    Alonso, V.
    Teule, A.
    Grande, E.
    Jimenez-Fonseca, P.
    Benavent, M.
    Alonso Gordoa, T.
    Custodio, A.
    Hierro Carbo, C.
    Lopez, C.
    Sevilla Garcia, I.
    Garcia-Carbonero, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S783 - S783
  • [19] A phase II trial of LEE011 in combination with everolimus in the treatment of advanced well differentiated neuroendocrine tumors of foregut origin.
    Raj, Nitya Prabhakar
    Kelly, Virginia
    Chan, Jennifer A.
    Dasari, A.
    Capanu, Marinela
    Tang, Laura
    Reidy, Diane Lauren
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [20] PAZONET: A PHASE II TRIAL OF PAZOPANIB AS A SEQUENCING TREATMENT IN PROGRESSIVE METASTATIC NEUROENDOCRINE TUMORS (NETS) PATIENTS (PTS), ON BEHALF OF THE SPANISH TASK FORCE FOR NETS (GETNE)
    Grande, E.
    Castellano, D.
    Garcia-Carbonero, R.
    Teule, A.
    Duran, I.
    Fuster, J.
    Sevilla, I.
    Escudero, P.
    Sastre, J.
    Casanovas, O.
    Ortega, L.
    Earl, J.
    Diez, J. J.
    de Velasco, G.
    Longo, F.
    Navarro, A.
    Pachon, V.
    Carrato, A.
    Salazar, R.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 377 - 377
12345